The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV.
作者信息
Lake Jordan E, Kitch Douglas W, Kantor Amy, Muthupillai Raja, Klingman Karin L, Vernon Christina, Belaunzaran-Zamudio Pablo F, Fichtenbaum Carl J, Heath Sonya, Perazzo Hugo, Corey Kathleen, Brown Todd T, Landay Alan, Sattler Fred, Erlandson Kristine M
机构信息
UTHealth Houston, Houston, Texas.
Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
出版信息
Ann Intern Med. 2024 Jun;177(6):835-838. doi: 10.7326/M23-3354. Epub 2024 Apr 30.
Abstract
摘要
相似文献
1
The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV.开放标签司美格鲁肽对HIV感染者代谢功能障碍相关脂肪性肝病的影响。
Ann Intern Med. 2024 Jun;177(6):835-838. doi: 10.7326/M23-3354. Epub 2024 Apr 30.
2
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.在患有代谢功能障碍相关脂肪性肝病的个体中，无论糖尿病和心脏代谢风险参数如何，司美格鲁肽均可带来相似的体重减轻：三项随机对照试验的事后分析
Diabetes Obes Metab. 2025 Feb;27(2):710-718. doi: 10.1111/dom.16065. Epub 2024 Nov 28.
3
Semaglutide in people with HIV-associated lipohypertrophy.司美格鲁肽用于治疗HIV相关脂肪代谢障碍患者。
Lancet Diabetes Endocrinol. 2024 Aug;12(8):504-505. doi: 10.1016/S2213-8587(24)00162-1. Epub 2024 Jul 1.
4
Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.口服司美格鲁肽对代谢相关脂肪性肝病合并 2 型糖尿病患者的疗效：一项前瞻性、多中心、观察性研究。
Diabetes Obes Metab. 2024 Nov;26(11):4958-4965. doi: 10.1111/dom.15898. Epub 2024 Sep 2.
5
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.司美格鲁肽在SLIM LIVER研究中对肌肉结构和功能的影响。
Clin Infect Dis. 2025 Feb 24;80(2):389-396. doi: 10.1093/cid/ciae384.
6
The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.胰高血糖素样肽-1 受体激动剂在代谢功能障碍相关脂肪性肝炎中的作用。
Diabetes Obes Metab. 2024 Jun;26(6):2001-2016. doi: 10.1111/dom.15524. Epub 2024 Mar 21.
7
Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study.接受胰高血糖素样肽-1 受体激动剂治疗的 MASLD 和 T2DM 患者的肝脏和骨骼肌变化有利：一项前瞻性队列研究。
Medicine (Baltimore). 2024 Jun 7;103(23):e38444. doi: 10.1097/MD.0000000000038444.
8
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1以及胰高血糖素受体/胰高血糖素样肽-1受体激动剂：代谢功能障碍相关脂肪性肝炎的新型治疗药物。
World J Gastroenterol. 2024 Dec 28;30(48):5205-5211. doi: 10.3748/wjg.v30.i48.5205.
9
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.在代谢功能障碍相关脂肪性肝炎患者中使用司美格鲁肽 2.4 mg：III 期 ESSENCE 试验的基线特征和设计。
Aliment Pharmacol Ther. 2024 Dec;60(11-12):1525-1533. doi: 10.1111/apt.18331. Epub 2024 Oct 16.
10
Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.胰高血糖素样肽 1 激动剂可能是治疗代谢功能障碍相关脂肪性肝病的有效药物。
World J Gastroenterol. 2024 Aug 14;30(30):3541-3547. doi: 10.3748/wjg.v30.i30.3541.
引用本文的文献
1
CROI 2025: Metabolic and Other Complications of HIV Infection.2025年逆转录病毒与机会性感染会议：HIV感染的代谢及其他并发症
Top Antivir Med. 2025 Jun 30;33(3):596-602.
2
From Weight Gain to Heart Strain: HIV Antiretroviral Adverse Effect Management in Primary Care.从体重增加到心脏负担：初级保健中HIV抗逆转录病毒药物不良反应的管理
J Prim Care Community Health. 2025 Jan-Dec;16:21501319251347869. doi: 10.1177/21501319251347869. Epub 2025 Jun 17.
3
Metabolic dysfunction-associated steatotic liver disease in people with HIV.HIV感染者中与代谢功能障碍相关的脂肪性肝病
Curr Opin HIV AIDS. 2025 Jul 1;20(4):350-358. doi: 10.1097/COH.0000000000000952. Epub 2025 May 21.
4
The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy.司美格鲁肽对HIV相关脂肪代谢障碍中炎症和免疫激活的影响。
Open Forum Infect Dis. 2025 Mar 20;12(4):ofaf152. doi: 10.1093/ofid/ofaf152. eCollection 2025 Apr.
5
Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.权衡：胰高血糖素样肽-1受体激动剂对艾滋病病毒感染者的作用
Top Antivir Med. 2024 Dec 23;32(5):579-588.
6
Individualizing Antiretroviral Therapy in the Older Patient.老年患者抗逆转录病毒疗法的个体化
Drugs Aging. 2025 Jan;42(1):9-20. doi: 10.1007/s40266-024-01168-z. Epub 2024 Dec 13.
7
Challenges of HIV Management in an Aging Population.老年人群中艾滋病毒管理的挑战
Curr HIV/AIDS Rep. 2024 Dec 12;22(1):8. doi: 10.1007/s11904-024-00718-9.
8
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.司美格鲁肽在SLIM LIVER研究中对肌肉结构和功能的影响。
Clin Infect Dis. 2025 Feb 24;80(2):389-396. doi: 10.1093/cid/ciae384.
本文引用的文献
1
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.随机临床试验：司美格鲁肽与安慰剂相比，可减少非酒精性脂肪性肝病患者的肝脏脂肪变性，但不能减少磁共振成像评估的肝脏硬度。
Aliment Pharmacol Ther. 2021 Nov;54(9):1150-1161. doi: 10.1111/apt.16608. Epub 2021 Sep 27.
2
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
3
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.降脂治疗与多种降脂治疗类别降低心血管风险的关联：一项随机对照试验的系统评价和荟萃回归分析。
Circulation. 2019 Oct 15;140(16):1308-1317. doi: 10.1161/CIRCULATIONAHA.119.041998. Epub 2019 Sep 18.
4
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
5
HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study.稳态模型评估的胰岛素抵抗是2型糖尿病患者心血管疾病的独立预测因素：来自维罗纳糖尿病并发症研究的前瞻性数据。
Diabetes Care. 2002 Jul;25(7):1135-41. doi: 10.2337/diacare.25.7.1135.
Zotero 插件